3624-25-7

Basic information

• Product Name: (3S)-3-(acetyloxy)-4-(trimethylammonio)butanoate
• Synonyms: L-Acetylcarnitine
• CAS NO: 3624-25-7
• Molecular Formula: C₉H₁₇NO₄
• Molecular Weight: 203.2356
• Mol File: 3624-25-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (3S)-3-(acetyloxy)-4-(trimethylammonio)butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-3-(acetyloxy)-4-(trimethylammonio)butanoate(3624-25-7)
• EPA Substance Registry System: (3S)-3-(acetyloxy)-4-(trimethylammonio)butanoate(3624-25-7)

Safety Data

• Hazardous Substances Data: 3624-25-7(Hazardous Substances Data)

Upstream product

• 851986-97-5 C₂₄H₄₀N₇O₁₇P₃S 
• 541-15-1 L-carnitine 
• 851986-96-4 C₂₃H₃₇N₆O₁₈P₃S 
• 108-24-7 acetic anhydride 
• 541-15-1 L-carnitine 
• 64-19-7 acetic acid 
• 6645-46-1 L-carnitine chloride 
• 75-36-5 acetyl chloride 
• 1415677-96-1 (2R)-2-(acetyloxy)-4-({[(2Z,3E)-2-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-1,2-dihydro-3H-indol-3-ylidene]amino}oxy)-N,N,N-trimethyl-4-oxobutan-1-aminium chloride 
• 5080-50-2 O-acetyl-L-carnitine hydrochloride 
• 161886-60-8 (R)-carnitine mesylate mesylate 
• 10017-44-4 (S)-(+)-3-hydroxy-4-(trimethylammonio)-butanoic acid chloride 
• 127-09-3 sodium acetate 

Downstream Products

• 5080-50-2 O-acetyl-L-carnitine hydrochloride 

Relevant articles and documents

Surface modification with cholesteryl acetyl carnitine, a novel cationic agent, elevates cancer cell uptake of the PEGylated liposomes

The present study aimed to synthesize cholesteryl acetyl carnitine (CAC), and surface modify the PEGylated liposomes with the intention of enhanced cancer cell uptake. For this, CAC synthesis was performed in amine-free esterification conditions and then four liposomal formulations of unmodified, CAC/PEG, and CAC + PEG-modified were prepared by ethanol injection method. Cytotoxicity of the liposomes was investigated in A549 cells, followed by cellular uptake assessments of coumarin 6 (C6)-loaded liposomes. The results of ATR-FTIR, 1HNMR, and 13CNMR demonstrated successful formation of CAC. A molecular docking study showed efficient binding affinities rather than carnitine to the active site of four carnitine transporters. Liposomal formulations possessed spherical morphology with a mean particle size range of 112–138 nm, narrow size distribution, and negative surface charge. All formulations had low cytotoxicity at 0.5 mg/ml, but high cytotoxicity at around 2.5 mg/ml. The lowest IC50 was obtained for CAC modified liposomes. CAC + PEG-modified liposomes had the highest cellular uptake. In conclusion, CAC + PEG modification of liposomes is an effective approach for increasing A549 cellular uptake, with low cytotoxicity at commonly applied liposome concentrations. The elevated uptake may be due to the involvement of the organic cation transporter, cationic structure, and the metabolic preference of CAC in cancer cells.

Synthesis method of acetyl-L-carnitine inner salt

The invention provides a method for synthesizing acetyl-L-carnitine simply.The method is characterized in that L-carnitine serving as a starting raw material and acetyl chloride serving as an acrylation reagent are subjected to an esterification reaction to obtain acetyl-L-carnitine hydrochloride, organic alkali is directly used for neutralizing to obtain acetyl-L-carnitine without separation, and high-quality acetyl-L-carnitine is obtained after recrystallization.According to the reaction related to the method, operation is simple, the condition is mild, aftertreatment is simple, the yield is high, and the method is a preparing way suitable for industrialization.

ACETYL-L-CARNITINE MALATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to acetyl-L-carnitine malate, a process for preparing the same, and a pharmaceutical composition comprising the same. The acetyl-L-carnitine malate of the present invention has good stability, solubility, and non-hygroscopicity to be effectively used for preparing a pharmaceutical composition.